Blog
About

1
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Corrigendum

      International Journal of Chronic Obstructive Pulmonary Disease

      Dove Medical Press

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tashkin DP, Doherty DE, Kerwin E, Matiz-Bueno CE, Knorr B, Shekar T, Banerjee S, Staudinger H. Efficacy and safety of a fixed-dose combination of mometasone furoate and formoterol fumarate in subjects with moderate to very severe COPD: results from a 52-week Phase III trial. Int J Chron Obstruct Pulmon Dis. 2012;7:43–55. In Table 4, the value at column 5, row 15 should have been 4 instead of 2. The corrected table is below. Table 4 Summary of treatment-emergent adverse events Number of subjects (%) MF/F 200/10 μg bid (n = 207) MF/F 400/10 μg bid (n = 217) MF 400 μg bid (n = 210) F 10 μg bid (n = 209) Placebo bid (n = 212) Treatment period (weeks 1–26)  Any AE 62 (30.0) 57 (26.3) 62 (29.5) 70 (33.5) 67 (31.6)  Severe or life-threatening AEs 6 (2.9) 9 (4.1) 15 (7.1) 16 (7.7) 12 (5.7)  Life-threatening AEs 0 4 (1.8) 4 (1.9) 4 (1.9) 3 (1.4)  Serious AEs 8 (3.9) 16 (7.4) 15 (7.1) 17 (8.1) 12 (5.7)  Discontinuations due to AEs 2 (1.0) 10 (4.6) 9 (4.3) 6 (2.9) 8 (3.8)  Deaths 1 (0.4) 1 (0.4) 3 (1.4) 3 (1.4) 1 (0.4)  Pneumonia 1 (0.5) 2 (0.9) 0 2 (1.0) 1 (0.5)  Treatment-related AEs 9 (4.3) 13 (6.0) 12 (5.7) 15 (7.2) 10 (4.7) Treatment period + safety extension (weeks 1–52)  Any AE 78 (37.7) 78 (35.9) 86 (41.07) 88 (42.1)  Severe or life-threatening AEs 7 (3.4) 21 (9.7) 19 (9.0) 24 (11.5)  Life-threatening AEs 1 (0.5) 6 (2.8) 4 (1.9) 6 (2.9)  Serious AEs 13 (6.3) 29 (13.4) 22 (10.5) 29 (13.9)  Discontinuations due to AEs 4 (1.9) 14 (6.5) 13 (6.2) 11 (5.3)  Deaths 1 (0.4) 3 (1.3) 3 (1.4) 8 (3.8)  Pneumonia 1 (0.5) 4 (1.8) 2 (1.0) 4 (1.9)  Treatment-related AEs 12 (5.8) 18 (8.3) 15 (7.1) 17 (8.1) Abbreviations: AE, adverse event; bid, twice daily; F, formoterol; MF, mometasone furoate; MF/F, mometasone furoate/formoterol fixed-dose combination.

          Related collections

          Author and article information

          Journal
          Int J Chron Obstruct Pulmon Dis
          Int J Chron Obstruct Pulmon Dis
          International Journal of COPD
          International Journal of Chronic Obstructive Pulmonary Disease
          Dove Medical Press
          1176-9106
          1178-2005
          2012
          2012
          16 November 2012
          : 7
          : 765
          Article
          copd-7-765
          10.2147/COPD.S32106
          3508664
          © 2012 Tashkin et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          Categories
          Corrigendum

          Respiratory medicine

          Comments

          Comment on this article